0001209191-18-038344.txt : 20180618
0001209191-18-038344.hdr.sgml : 20180618
20180618164356
ACCESSION NUMBER: 0001209191-18-038344
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180614
FILED AS OF DATE: 20180618
DATE AS OF CHANGE: 20180618
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vachon Mark
CENTRAL INDEX KEY: 0001614018
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35966
FILM NUMBER: 18905145
MAIL ADDRESS:
STREET 1: GOODWIN PROCTER LLP
STREET 2: 53 STATE STREET
CITY: BOSTON
STATE: MA
ZIP: 02109
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: bluebird bio, Inc.
CENTRAL INDEX KEY: 0001293971
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 339-499-9300
MAIL ADDRESS:
STREET 1: 60 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc
DATE OF NAME CHANGE: 20040616
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-14
0
0001293971
bluebird bio, Inc.
BLUE
0001614018
Vachon Mark
C/O BLUEBIRD BIO, INC.
60 BINNEY STREET
CAMBRIDGE
MA
02142
1
0
0
0
Common Stock
2018-06-14
4
S
0
700
189.825
D
300
D
Common Stock
2018-06-14
4
S
0
300
190.3833
D
0
D
The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2017.
The range in prices for the transaction reported on this line was $189.25 to $190.225. The average weighted price was $189.825. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
The range in prices for the transaction reported on this line was $190.25 to $190.45. The average weighted price was $190.3833. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
/s/ Jason F. Cole, Attorney-in-Fact
2018-06-18